Modern close ties with Canada. The company has agreed with the country’s government to begin production of mRNA vaccines, through the establishment of a vaccine manufacturing plant in the province of Quebec, as reported by the company in a statement. The agreement is valid for ten years.
Once operational, the facility is expected to provide access to a portfolio of Canadian-made mRNA vaccines against various respiratory viruses, including Covid-19, seasonal flu, respiratory syncytial virus (RSV) and other possible respiratory viruses.
In the event of a future pandemic, it is expected that the facility can be activated on an urgent basis to support Canada in direct access to rapid response capabilities, with the ability to adapt and adjust manufacturing. The intent is to address emerging new or existing viruses.
“The planned research and development (R&D) commitments will contribute to the growth of the life sciences ecosystem in Canada, providing a significant boost to the Canadian government’s life sciences and biomanufacturing strategy,” said Patricia. Gauthier, President and CEO of Moderna Canada.
Moderna explained that its vaccine against Covid-19 is about 93% effective
mRNA vaccines do not contain actual viruses, but instead provide instructions for human cells to make proteins that mimic part of the coronavirus. Last week, Moderna explained that its Covid-19 vaccine has a effectiveness of about 93% during the six months after the second dose.
In Spain, Moderna has strengthened its position in these first months of 2022. In fact, the American biotechnology company, which has an agreement in the country with Rovi Pharmaceutical Laboratories, plans to end the year manufacturing 500 million doses of its anti-Covid-19 vaccine. To date, the company has manufactured just over 350 million doses of its Covid-19 vaccine in Spain, which it has distributed to more than sixty countries.
–
/data/photo/2022/05/02/626f60fcdbb0b.jpeg?resize=150%2C150&ssl=1)
